We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Centene (CNC), Cityblock Partner to Enhance Value-Based Care
Read MoreHide Full Article
Centene Corporation’s (CNC - Free Report) wholly-owned subsidiary Sunshine Health recently partnered with Cityblock to offer care coordination and primary care services to Medicaid members in 11 Central Florida Countries. This move is aimed at providing whole health services, seamless care coordination and clinical services. This partnership is an extension of CNC’s partnership with Cityblock in Ohio and New York.
This move bodes well for Centene as it will be able to provide value-based care to its customers. Members will be able to access wrap-around services 24/7 and virtually see the multidisciplinary team in addition to in-home and local clinics. This highlights that CNC is addressing the growing demand for convenient and flexible healthcare services, given the rapid advancement in technology. Virtual care will also drive more engagement and adherence to plans, thereby improving health outcomes and reducing unnecessary inpatient admissions and emergency department visits.
Cityblock is the perfect partner for Sunshine Health, given its care model, to cater to members with complex care needs and who are more likely at higher risk for poor health conditions. Per Cityblock’s 2024 Equity in Action report, its care model has led to increased clinical continuity and engagement and reduced avoidable inpatient admissions. Such value propositions are expected to reduce medical costs for CNC, enabling it to report better profit margins in the future.
Moves like these should poise CNC well for growth as offering innovative value-based care services should differentiate it from its competitors. Enhanced offerings will enable it to attract providers and members who value patient-centered and integrated care. Moves like these should drive sustainability and long-term growth.
Shares of Centene have gained 20.6% in the past year compared with the industry’s 9.1% growth. CNC currently carries a Zacks Rank #3 (Hold).
Medpace’s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 12.8%. The consensus estimate for MEDP’s 2024 earnings and revenues suggests an improvement of 27.1% and 14.9%, respectively, from the 2023 reported figures.
The consensus estimate for Medpace’s 2024 earnings has moved 4.5% north in the past 30 days. Shares of MEDP have gained 92.4% in the past year.
Boston Scientific’s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 7.5%. The consensus estimate for BSX’s 2024 earnings and revenues suggests an improvement of 13.2% and 12.3% from the respective 2023 figures.
The consensus estimate for Boston Scientific’s 2024 earnings has moved 3.1% north in the past 30 days. Shares of BSX have gained 45.1% in the past year.
DaVita’s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 29.4%. The consensus estimate for DVA’s 2024 earnings and revenues suggests an improvement of 13.6% and 5%, respectively, from the 2023 figures.
The consensus estimate for DaVita’s 2024 earnings has moved 1.4% north in the past seven days. Shares of DVA have gained 40% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Centene (CNC), Cityblock Partner to Enhance Value-Based Care
Centene Corporation’s (CNC - Free Report) wholly-owned subsidiary Sunshine Health recently partnered with Cityblock to offer care coordination and primary care services to Medicaid members in 11 Central Florida Countries. This move is aimed at providing whole health services, seamless care coordination and clinical services. This partnership is an extension of CNC’s partnership with Cityblock in Ohio and New York.
This move bodes well for Centene as it will be able to provide value-based care to its customers. Members will be able to access wrap-around services 24/7 and virtually see the multidisciplinary team in addition to in-home and local clinics. This highlights that CNC is addressing the growing demand for convenient and flexible healthcare services, given the rapid advancement in technology. Virtual care will also drive more engagement and adherence to plans, thereby improving health outcomes and reducing unnecessary inpatient admissions and emergency department visits.
Cityblock is the perfect partner for Sunshine Health, given its care model, to cater to members with complex care needs and who are more likely at higher risk for poor health conditions. Per Cityblock’s 2024 Equity in Action report, its care model has led to increased clinical continuity and engagement and reduced avoidable inpatient admissions. Such value propositions are expected to reduce medical costs for CNC, enabling it to report better profit margins in the future.
Moves like these should poise CNC well for growth as offering innovative value-based care services should differentiate it from its competitors. Enhanced offerings will enable it to attract providers and members who value patient-centered and integrated care. Moves like these should drive sustainability and long-term growth.
Shares of Centene have gained 20.6% in the past year compared with the industry’s 9.1% growth. CNC currently carries a Zacks Rank #3 (Hold).
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks from the Medical space are Medpace Holdings, Inc. (MEDP - Free Report) , Boston Scientific Corporation (BSX - Free Report) and DaVita Inc. (DVA - Free Report) . While Medpace sports a Zacks Rank #1 (Strong Buy) at present, Boston Scientific and DaVita carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace’s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 12.8%. The consensus estimate for MEDP’s 2024 earnings and revenues suggests an improvement of 27.1% and 14.9%, respectively, from the 2023 reported figures.
The consensus estimate for Medpace’s 2024 earnings has moved 4.5% north in the past 30 days. Shares of MEDP have gained 92.4% in the past year.
Boston Scientific’s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 7.5%. The consensus estimate for BSX’s 2024 earnings and revenues suggests an improvement of 13.2% and 12.3% from the respective 2023 figures.
The consensus estimate for Boston Scientific’s 2024 earnings has moved 3.1% north in the past 30 days. Shares of BSX have gained 45.1% in the past year.
DaVita’s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 29.4%. The consensus estimate for DVA’s 2024 earnings and revenues suggests an improvement of 13.6% and 5%, respectively, from the 2023 figures.
The consensus estimate for DaVita’s 2024 earnings has moved 1.4% north in the past seven days. Shares of DVA have gained 40% in the past year.